Dexcom (DXCM) Q4 2019 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2019 earnings summary
4 Nov, 2026Executive summary
2019 revenue rose 43% to $1.476B, and net income reached $101.1M, marking the first full year of GAAP profitability.
Global active users reached an estimated 650,000 at year-end; G6 capacity doubled during 2019 as patient additions accelerated.
Financial highlights
FY19 revenue was $1,476.0M, up 43% YoY; gross profit was $931.5M, up 40%, and operating income was $142.3M versus a $186.3M operating loss in 2018.
FY19 net income was $101.1M versus a $127.1M net loss in 2018; diluted EPS was $1.10 versus a loss of $1.44.
Q4 revenue was $462.8M, gross profit $309.3M, operating expenses $207.8M, net income $92.7M, and diluted EPS $1.00.
Cash, cash equivalents and short-term marketable securities totaled $1,533.3M at year-end, up $147.7M YoY; operating cash flow was $314.5M.
Sensor and other revenue was 78% of FY19 total, versus 75% in 2018; reusable hardware contributed 22%, versus 25%.
Outlook and guidance
Capacity expansion is planned to continue in 2020 to support accelerating new-patient growth and sustain growth momentum.
Medicare G6 rollout continues; G6 launches are planned or expanding in selected international markets to broaden access.
Significant investment continues in next-generation disposable G7, whose smaller form factor is expected to improve user experience.
Longer-term opportunities include broader Type 2, prediabetes, pregnancy and hospital populations, alongside expanded global access and connected-device integration.
Latest events from Dexcom
- Revenue growth and margin gains were offset by lower earnings and a major Verily charge.DXCM
Q4 2021 - Revenue grew 19% as G7 clearance and expanded CGM access strengthened growth prospects.DXCM
Q4 2022 - 31% revenue growth and 66% gross margin, with earnings lifted by a major tax benefit.DXCM
Q4 2020 - G6-led revenue topped $1B as launch investment and the Verily charge widened losses.DXCM
Q4 2018 - Q3 revenue and margins grew, lifting FY2026 guidance and supporting a new $1B buyback.DXCM
Q3 2026 - Q4 revenue grew 26% organically as FDA submissions and G7 integrations advanced.DXCM
Q4 2023 - CONNECT data, expanded coverage, and product innovation set stage for accelerated growth.DXCM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 13%, net income 39%, margins and guidance up, $600M shares repurchased.DXCM
Q2 2026 - Q3 2024 saw 2–3% revenue growth, strong international gains, and a $750M share repurchase.DXCM
Q3 2024